Logos Global Management LP
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 27, 2024), Logos Global Management LP reported 50 stock positions worth $867.8 million. Its top holding was Ideaya Biosciences (IDYA) at 6.9% of the portfolio, followed by Argenx SE - ADR (ARGX, 6.7%) and Merus (MRUS, 5.8%). Compared with Q1 2024, it opened 16 new positions, sold out of 15, added to 12 and reduced 15. The biggest buy was a new position in Argenx SE - ADR (ARGX) and the biggest sale an exit from Immunocore Holdings PLC-ADR (IMCR).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $867.8M (Q2 2024)
- SEC Filing
- 0001172661-24-003755 ↗ filed Aug 27, 2024
Holdings Value
Holdings 50 stocks · $867.8M
| IDYA Ideaya Biosciences Inc. | 6.88% | 1,700,000 | $59.7M | Add +13.3% |
| ARGX Argenx SE - ADR | 6.69% | 135,000 | $58.1M | New |
| MRUS Merus NV | 5.80% | 850,000 | $50.3M | New |
| RVMD Revolution Medicines Inc. | 5.37% | 1,200,000 | $46.6M | New |
| GPCR Structure Therapeutics Inc. | 4.98% | 1,100,000 | $43.2M | Add +52.8% |
| IRON Disc Medicine Inc. | 4.80% | 925,000 | $41.7M | New |
| OCUL Ocular Therapeutix Inc. | 4.06% | 5,150,000 | $35.2M | Reduce -11.4% |
| OLMA Olema Pharmaceuticals Inc. | 4.00% | 3,208,875 | $34.7M | Reduce -26.8% |
| VERA Vera Therapeutics Inc. | 3.96% | 950,000 | $34.4M | Add +65.2% |
| MLTX Moonlake Immunotherapeutics | 3.80% | 750,000 | $33.0M | New |
| JANX Janux Therapeutics Inc. | 3.62% | 750,000 | $31.4M | Add +400.0% |
| XNCR Xencor Inc. | 3.27% | 1,500,000 | $28.4M | Add +130.8% |
| SLN Silence Therapeutics PLC-ADR | 3.23% | 1,476,061 | $28.0M | No change |
| SRPT Sarepta Therapeutics Inc. | 2.73% | 150,000 | $23.7M | Reduce -62.5% |
| AKRO Akero Therapeutics Inc. | 2.16% | 800,000 | $18.8M | No change |
| DSGN Design Therapeutics Inc. | 1.94% | 5,032,501 | $16.9M | No change |
| ANNX Annexon Inc. | 1.86% | 3,300,000 | $16.2M | Add +8.2% |
| APLS Apellis Pharmaceuticals Inc. | 1.77% | 400,000 | $15.3M | Reduce -50.0% |
| IMVT Immunovant Inc. | 1.75% | 575,000 | $15.2M | Reduce -67.6% |
| NUVL Nuvalent Inc. Class A | 1.70% | 195,000 | $14.8M | New |
| XENE Xenon Pharmaceuticals Inc. | 1.68% | 375,000 | $14.6M | New |
| IONS Ionis Pharmaceuticals Inc. | 1.65% | 300,000 | $14.3M | New |
| STOK Stoke Therapeutics Inc. | 1.63% | 1,050,000 | $14.2M | New |
| ERAS Erasca Inc. | 1.60% | 5,900,000 | $13.9M | New |
| ELVN Enliven Therapeutics Inc. | 1.60% | 595,000 | $13.9M | Reduce -62.2% |
| SYRE Spyre Therapeutics Inc. | 1.56% | 575,000 | $13.5M | Add +130.0% |
| ENGN Engene Holdings Inc. | 1.30% | 1,200,000 | $11.3M | Add +50.0% |
| CYBIN INC | 1.25% | 40,000,000 | $10.8M | No change |
| SKYE Skye Bioscience Inc. | 1.20% | 1,301,518 | $10.4M | New |
| ELEV Elevation Oncology Inc. | 1.20% | 3,850,000 | $10.4M | Add +285.0% |
| DYN Dyne Therapeutics Inc. | 1.08% | 265,000 | $9.4M | Reduce -84.7% |
| BHVN Biohaven Ltd. | 1.00% | 250,000 | $8.7M | New |
| RLAY Relay Therapeutics Inc. | 0.98% | 1,300,000 | $8.5M | New |
| TRVI Trevi Therapeutics Inc. | 0.96% | 2,800,000 | $8.3M | Add +27.3% |
| RCKT Rocket Pharmaceuticals Inc. | 0.87% | 350,000 | $7.5M | Reduce -73.1% |
| CMPS Compass Pathways PLC | 0.81% | 1,159,030 | $7.0M | Add +349.3% |
| AVTX Avalo Therapeutics Inc. | 0.77% | 539,079 | $6.7M | New |
| LCTX Lineage Cell Therapeutics Inc. | 0.54% | 4,700,000 | $4.7M | Reduce -24.8% |
| ATYR Atyr Pharma Inc. | 0.54% | 3,000,000 | $4.7M | Reduce -3.2% |
| ATXS Astria Therapeutics Inc. | 0.52% | 500,000 | $4.5M | Reduce -59.8% |
| RAPP Rapport Therapeutics Inc. | 0.50% | 208,910 | $4.4M | New |
| NXTC Nextcure Inc. | 0.46% | 2,500,000 | $4.0M | Add +29.9% |
| NMRA Neumora Therapeutics Inc. | 0.34% | 300,000 | $2.9M | Reduce -21.5% |
| ALLK Allakos LLC | 0.33% | 2,900,000 | $2.9M | No change |
| ADVM Adverum Biotechnologies Inc. | 0.33% | 416,666 | $2.9M | Reduce -72.2% |
| APLT Applied Therapeutics Inc. | 0.31% | 600,000 | $2.7M | Reduce -55.6% |
| RNAC Cartesian Therapeutics Inc. | 0.28% | 90,000 | $2.4M | New |
| UNICYCIVE THERAPEUTICS INC | 0.20% | 3,469,927 | $1.7M | No change |
| IOBTQ Io Biotech Inc. | 0.07% | 493,827 | $578K | No change |
| BOLD Boundless Bio Inc. | 0.05% | 117,806 | $433K | Reduce -41.1% |
Options reported separately and not counted above: XBI puts ($185.4M), SRPT calls ($79.0M), APLS calls ($76.7M), GPCR calls ($17.7M), FULC calls ($9.3M), ANNX calls ($7.3M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $11K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $11K | No change |
Total filed on the 13F, all lines: $867.8M.
Portfolio Sells Q1 2024 → Q2 2024
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −6.16 |
| IMVT Immunovant Inc. | Reduce -67.6% | 1.75% | −4.29 |
| DYN Dyne Therapeutics Inc. | Reduce -84.7% | 1.08% | −4.09 |
| APLS Apellis Pharmaceuticals Inc. | Reduce -50.0% | 1.77% | −3.18 |
| GERN Geron Corp. | Sold out | 0.00% | −3.13 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −2.87 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -73.1% | 0.87% | −2.82 |
| SRPT Sarepta Therapeutics Inc. | Reduce -62.5% | 2.73% | −2.72 |
| ADVM Adverum Biotechnologies Inc. | Reduce -72.2% | 0.33% | −1.90 |
| OCUL Ocular Therapeutix Inc. | Reduce -11.4% | 4.06% | −1.41 |
| CGON CG Oncology Inc. | Sold out | 0.00% | −1.39 |
| ATXS Astria Therapeutics Inc. | Reduce -59.8% | 0.52% | −1.32 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −1.31 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −1.29 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −1.26 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -26.8% | 4.00% | −1.22 |
| ELVN Enliven Therapeutics Inc. | Reduce -62.2% | 1.60% | −1.18 |
| IMTX Immatics NV | Sold out | 0.00% | −1.11 |
| PRAX Praxis Precision Medicines I | Sold out | 0.00% | −0.96 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −0.88 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −0.74 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −0.67 |
| APLT Applied Therapeutics Inc. | Reduce -55.6% | 0.31% | −0.64 |
| LCTX Lineage Cell Therapeutics Inc. | Reduce -24.8% | 0.54% | −0.43 |
| NMRA Neumora Therapeutics Inc. | Reduce -21.5% | 0.34% | −0.31 |
| BOLD Boundless Bio Inc. | Reduce -41.1% | 0.05% | −0.25 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −0.24 |
| ATYR Atyr Pharma Inc. | Reduce -3.2% | 0.54% | −0.10 |
| IMUX Immunic Inc. | Sold out | 0.00% | −0.06 |
| CYPH Cypherpunk Technologies Inc. | Sold out | 0.00% | −0.01 |
Portfolio Buys Q1 2024 → Q2 2024
| ARGX Argenx SE - ADR | New | 6.69% | +6.69 |
| MRUS Merus NV | New | 5.80% | +5.80 |
| RVMD Revolution Medicines Inc. | New | 5.37% | +5.37 |
| IRON Disc Medicine Inc. | New | 4.80% | +4.80 |
| MLTX Moonlake Immunotherapeutics | New | 3.80% | +3.80 |
| JANX Janux Therapeutics Inc. | Add +400.0% | 3.62% | +3.03 |
| XNCR Xencor Inc. | Add +130.8% | 3.27% | +1.76 |
| GPCR Structure Therapeutics Inc. | Add +52.8% | 4.98% | +1.73 |
| NUVL Nuvalent Inc. Class A | New | 1.70% | +1.70 |
| XENE Xenon Pharmaceuticals Inc. | New | 1.68% | +1.68 |
| IONS Ionis Pharmaceuticals Inc. | New | 1.65% | +1.65 |
| STOK Stoke Therapeutics Inc. | New | 1.63% | +1.63 |
| ERAS Erasca Inc. | New | 1.60% | +1.60 |
| VERA Vera Therapeutics Inc. | Add +65.2% | 3.96% | +1.35 |
| SKYE Skye Bioscience Inc. | New | 1.20% | +1.20 |
| BHVN Biohaven Ltd. | New | 1.00% | +1.00 |
| RLAY Relay Therapeutics Inc. | New | 0.98% | +0.98 |
| AVTX Avalo Therapeutics Inc. | New | 0.77% | +0.77 |
| ELEV Elevation Oncology Inc. | Add +285.0% | 1.20% | +0.66 |
| CMPS Compass Pathways PLC | Add +349.3% | 0.81% | +0.62 |
| SYRE Spyre Therapeutics Inc. | Add +130.0% | 1.56% | +0.56 |
| RAPP Rapport Therapeutics Inc. | New | 0.50% | +0.50 |
| RNAC Cartesian Therapeutics Inc. | New | 0.28% | +0.28 |
| TRVI Trevi Therapeutics Inc. | Add +27.3% | 0.96% | +0.16 |
| NXTC Nextcure Inc. | Add +29.9% | 0.46% | +0.01 |
| IDYA Ideaya Biosciences Inc. | Add +13.3% | 6.88% | −0.05 |
| ENGN Engene Holdings Inc. | Add +50.0% | 1.30% | −0.05 |
| ANNX Annexon Inc. | Add +8.2% | 1.86% | −0.44 |
Options Activity Q1 2024 → Q2 2024
| XBI SS SPDR S&P Biotech ETF | put | New | 2,000,000 | $185.4M |
| SRPT Sarepta Therapeutics Inc. | call | Reduce -58.3% | 500,000 | $79.0M |
| APLS Apellis Pharmaceuticals Inc. | call | New | 2,000,000 | $76.7M |
| ALNY Alnylam Pharmaceuticals Inc. | call | Sold out | 500,000 | $74.7Mbefore exit |
| ATXS Astria Therapeutics Inc. | call | Sold out | 1,000,000 | $14.1Mbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | Add +50.0% | 1,500,000 | $9.3M |
| ANNX Annexon Inc. | call | Add +50.0% | 1,500,000 | $7.3M |
| LRMR Larimar Therapeutics Inc. | call | Sold out | 700,000 | $5.3Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |